GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

FAT JABS have taken the nation’s waistline by storm – trimming inches and helping thousands shed weight, and fast. But it ...

Wright added that RA is also a “ripe” area for research into GLP-1 agonism ... “Gastroparesis may also occur, along with hypoglycemia, especially when combined with other medications ...

When a GLP-1 RA is prescribed along with insulin, it can increase the odds of hypoglycemia. Because GLP-1 RAs slow digestion, they may affect how some medications are absorbed. If you have ...

Secondary outcomes included the individual outcomes and hypoglycemia ... combination therapy of a thiazolidinedione plus a GLP-1 RA in patients with T2D,” the authors of an invited commentary ...

Current GLP-1 RA drugs, such as semaglutide and the dual ... including use of exogenous insulin, fear of hypoglycemia leading to caloric intake and lack of exercise, psychological factors, and ...

The study found an increased risk of hypoglycemia with combination therapy, which decreased with prolonged use. Thiazolidinedione monotherapy was linked to higher mortality compared to GLP-1 RA ...

Share on Pinterest GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.